Creating new tools to target brain receptors involved in Alzheimer's disease
Official title: Developing an integrated pipeline for routine generation of orthogonal GPCR-targeting nanobodies
Funded at Vitan-Biotech, LLC · NIH-10603669 · Data updated 2026-11-12
This study is working on a new way to create tiny proteins that can help target brain receptors involved in Alzheimer's disease, with the hope of finding better treatments for people living with this condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vitan-Biotech, LLC NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | September 22, 2023 |
| Project end | September 21, 2025 |
| Funding year | 2023 |
| Award (this year) | $218,622 |
| NIH project number | 1R43GM149069-01 |
| Project ID | NIH-10603669 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related neurological disorders.
✕Less likely to help
Patients with neurological conditions not related to GPCR dysfunction may not benefit from this research.
What this research studies
This research focuses on developing a new method to create nanobodies that specifically target G-protein coupled receptors (GPCRs) linked to neurological conditions like Alzheimer's disease. By using advanced techniques, the researchers aim to produce these nanobodies more efficiently than traditional methods, which often struggle with the complexity of GPCRs. This could lead to better understanding and treatment options for patients with Alzheimer's and other related disorders. The project will utilize innovative cell-free systems to generate these important therapeutic agents.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease and improve the quality of life for patients.
How similar studies have gone: While the approach of using nanobodies is promising, the specific application to GPCRs in Alzheimer's disease is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
Vitan-Biotech, LLC
Aurora, United States Active
Researchers
- Principal investigator: Zhou, Xichun — Vitan-Biotech, LLC
- Study coordinator: Zhou, Xichun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.